title: The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).
abstract: Tumor-induced dysfunction of immune cells is a common problem in cancer. Tumors induce immune suppression by many different mechanisms, including accumulation of regulatory T cells (Treg). Adaptive Treg (Tr1) generated in the tumor microenvironment express CD39 and CD73 ectonucleotidases, produce adenosine and are COX2+PGE2+. Adenosine and PGE2 produced by Tr1 or tumor cells bind to their respective receptors on the surface of T effector cells (Teff) and cooperate in up-regulating cytosolic 3'5'-cAMP levels utilizing adenylyl cyclase isoform 7 (AC-7). In Teff, increased cAMP mediates suppression of anti-tumor functions. Treg, in contrast to Teff, seem to require high cAMP levels for mediating suppression. This differential requirement of Treg and Teff for cAMP offers an opportunity for pharmacologic interventions using selected inhibitors of the adenosine/PGE2 pathways. Blocking of adenosine/PGE2 production by Tr1 or blocking binding of these factors to their receptors on T cells or inhibition of cAMP synthesis in Teff all represent novel therapeutic strategies that used in combination with conventional therapies could restore anti-tumor functions of Teff . At the same time, these inhibitors could disarm Tr1 cells by depriving them of the factors promoting their generation and activity or by down-regulating 3'5'-cAMP levels. Thus, the pharmacologic control of Treg-Teff interactions offers a novel strategy for restoration of anti-tumor Teff functions and silencing of Treg. Used in conjunction with anti-cancer drugs or with immune therapies, this strategy has a potential to improve therapeutic effects by preventing or reversing tumor-induced immune suppression.
authors.affiliation: University of Pittsburgh Cancer Institute, Research Pavilion at the Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh, PA 15213-1863, USA. whitesidetl@upmc.edu
authors.forename: T L
authors.initials: TL
authors.lastname: Whiteside
authors.forename: M
authors.initials: M
authors.lastname: Mandapathil
authors.forename: P
authors.initials: P
authors.lastname: Schuler
mesh_terms: D000241:Adenosine / Q000037:antagonists & inhibitors / Q000276:immunology*; D000818:Animals; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D059016:Tumor Microenvironment / Q000276:immunology
chemical_list: D000241:Adenosine; D015232:Dinoprostone
references.citation: Blood. 2007 Aug 15;110(4):1225-32
references.pmid: 17449799
references.citation: Sci Transl Med. 2011 May 18;3(83):83ra40
references.pmid: 21593400
references.citation: Carcinogenesis. 2009 Mar;30(3):377-86
references.pmid: 19136477
references.citation: Cancer Treat Res. 2006;130:103-24
references.pmid: 16610705
references.citation: Adv Cancer Res. 2010;107:57-117
references.pmid: 20399961
references.citation: Drug Discov Today. 2009 Oct;14(19-20):982-91
references.pmid: 19638320
references.citation: Nat Med. 2004 Sep;10(9):942-9
references.pmid: 15322536
references.citation: Cancer Res. 1997 Jul 1;57(13):2602-5
references.pmid: 9205063
references.citation: Int J Cancer. 2010 Aug 15;127(4):759-67
references.pmid: 20518016
references.citation: J Immunol. 2010 Jul 1;185(1):335-44
references.pmid: 20505140
references.citation: Int J Oncol. 2008 Mar;32(3):527-35
references.pmid: 18292929
references.citation: Crit Rev Immunol. 2007;27(1):61-95
references.pmid: 17430097
references.citation: J Surg Res. 2008 Jun 15;147(2):240-6
references.pmid: 18498876
references.citation: Cancer Immunol Immunother. 2007 Sep;56(9):1429-42
references.pmid: 17265021
references.citation: J Exp Med. 2007 Jun 11;204(6):1257-65
references.pmid: 17502665
references.citation: Immunol Rev. 2008 Apr;222:192-205
references.pmid: 18364003
references.citation: J Immunol. 2003 Dec 15;171(12):6891-9
references.pmid: 14662896
references.citation: Cancer Res. 2009 Apr 1;69(7):3095-104
references.pmid: 19276353
references.citation: Cancer Res. 2010 Aug 15;70(16):6407-11
references.pmid: 20682793
references.citation: Clin Cancer Res. 2007 Nov 1;13(21):6301-11
references.pmid: 17975141
references.citation: J Immunol. 1996 Feb 15;156(4):1349-55
references.pmid: 8568233
references.citation: Science. 2006 Sep 29;313(5795):1960-4
references.pmid: 17008531
references.citation: Blood. 2011 Apr 21;117(16):4387-93
references.pmid: 21346249
references.citation: Oncogene. 2010 Sep 30;29(39):5346-58
references.pmid: 20661219
references.citation: Endocr Metab Immune Disord Drug Targets. 2006 Sep;6(3):239-47
references.pmid: 17017975
references.citation: Gut. 2006 Jan;55(1):115-22
references.pmid: 16118353
references.citation: Cancer Immunol Immunother. 2008 Nov;57(11):1611-23
references.pmid: 18327580
references.citation: J Immunol. 2009 Feb 1;182(3):1469-80
references.pmid: 19155494
references.citation: Cancer Immunol Immunother. 2011 Jan;60(1):111-22
references.pmid: 20960188
references.citation: Trends Immunol. 2008 Mar;29(3):99-102
references.pmid: 18258482
references.citation: Clin Cancer Res. 2009 Nov 15;15(22):6745-7
references.pmid: 19903779
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6674-82
references.pmid: 18927310
references.citation: Oncogene. 2008 Oct 6;27(45):5904-12
references.pmid: 18836471
references.citation: J Immunol. 2011 Jul 15;187(2):676-83
references.pmid: 21677139
references.citation: J Biol Chem. 2007 Apr 20;282(16):11613-7
references.pmid: 17329241
references.citation: FEBS Lett. 1998 Jul 3;430(3):227-30
references.pmid: 9688544
references.citation: Mol Immunol. 2010 Jan;47(4):678-84
references.pmid: 19939455
references.citation: Crit Rev Oncog. 2008;14(1):57-77
references.pmid: 19105570
references.citation: Expert Opin Biol Ther. 2010 Jul;10(7):1019-35
references.pmid: 20415597
references.citation: Circ Res. 1990 Mar;66(3):754-62
references.pmid: 1689616
references.citation: Clin Cancer Res. 2002 Oct;8(10):3137-45
references.pmid: 12374681
references.citation: Clin Cancer Res. 2011 Feb 15;17(4):841-8
references.pmid: 21177412
references.citation: Cancer Immunol Immunother. 2012 Jun;61(6):771-82
references.pmid: 22057678
references.citation: Blood. 2008 Aug 1;112(3):610-8
references.pmid: 18519811
references.citation: J Biol Chem. 2010 Mar 5;285(10):7176-86
references.pmid: 19858205
references.citation: Immunity. 2009 May;30(5):636-45
references.pmid: 19464986
references.citation: Lancet Oncol. 2001 Sep;2(9):544-51
references.pmid: 11905709
references.citation: Cancer Res. 2006 Jun 1;66(11):5527-36
references.pmid: 16740684
references.citation: Cancer Immunol Immunother. 2011 Aug;60(8):1161-71
references.pmid: 21626032
references.citation: J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S272-83
references.pmid: 20061007
references.citation: Blood. 1998 Dec 1;92(11):4150-66
references.pmid: 9834220
references.citation: J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
references.pmid: 18270337
references.citation: Br J Pharmacol. 2008 Mar;153 Suppl 1:S457-64
references.pmid: 18311159
references.citation: Cancer Immun. 2009 Apr 02;9:3
references.pmid: 19338264
references.citation: Cancer Res. 2007 Sep 15;67(18):8865-73
references.pmid: 17875728
references.citation: Cell Oncol. 2009;31(6):475-85
references.pmid: 19940363
references.citation: Immunity. 2009 May;30(5):646-55
references.pmid: 19464987
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54
references.pmid: 17671115
references.citation: Science. 1993 Jul 23;261(5120):466-9
references.pmid: 8101391
references.citation: J Immunol. 2010 Aug 15;185(4):1993-8
references.pmid: 20686167
references.citation: J Immunol Methods. 2011 Jun 30;369(1-2):59-68
references.pmid: 21513715
references.citation: Eur J Immunol. 2009 Jan;39(1):241-53
references.pmid: 19089817
references.citation: Nat Rev Cancer. 2010 Mar;10(3):181-93
references.pmid: 20168319
references.citation: Cancer Immunol Immunother. 2007 May;56(5):641-8
references.pmid: 16960692
references.citation: Sci Signal. 2011 Mar 01;4(162):ra12
references.pmid: 21364186
references.citation: Clin Cancer Res. 2008 Oct 1;14(19):5947-52
references.pmid: 18829471
references.citation: J Immunol. 2009 Mar 15;182(6):3801-8
references.pmid: 19265159
references.citation: Surg Oncol Clin N Am. 2007 Oct;16(4):755-74, viii
references.pmid: 18022543
references.citation: J Mol Cell Biol. 2010 Feb;2(1):30-6
references.pmid: 19648226
references.citation: J Biol Chem. 2010 Sep 3;285(36):27571-80
references.pmid: 20558731
references.citation: J Exp Med. 2002 Sep 2;196(5):619-28
references.pmid: 12208877
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3706-15
references.pmid: 18559587
references.citation: J Immunol. 2004 Jul 15;173(2):932-44
references.pmid: 15240680
references.citation: Front Biosci. 2008 Jan 01;13:1634-45
references.pmid: 17981655
references.citation: Annu Rev Immunol. 2004;22:657-82
references.pmid: 15032592
references.citation: Cancer Immunol Immunother. 2011 Aug;60(8):1127-35
references.pmid: 21479639
references.citation: J Mol Med (Berl). 2010 Jun;88(6):577-88
references.pmid: 20225066
references.citation: Cancer Immun. 2008 Dec 04;8:16
references.pmid: 19053167
references.citation: Oncogene. 2008 Oct 6;27(45):5869-85
references.pmid: 18836468
references.citation: J Exp Med. 2001 Jun 4;193(11):1285-94
references.pmid: 11390435
references.citation: Immunol Rev. 2001 Aug;182:68-79
references.pmid: 11722624
references.citation: Recent Pat Anticancer Drug Discov. 2008 Jan;3(1):55-62
references.pmid: 18289124
references.citation: Acta Biochim Biophys Sin (Shanghai). 2009 May;41(5):362-9
references.pmid: 19430700
references.citation: Cancer Immunol Immunother. 2011 Aug;60(8):1153-60
references.pmid: 21553145
references.citation: Nat Rev Drug Discov. 2008 Sep;7(9):759-70
references.pmid: 18758473
references.citation: Immunol Rev. 2006 Aug;212:28-50
references.pmid: 16903904